Delisting risk
Scienture (SCNX)
Specialty drug developer commercializing differentiated formulations for cardiovascular and CNS care.
$0.3810
Pre-market+0.01 (+2.97%)
At close$0.3700(+0.54%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions14 holders · as of Mar 31, 2026 | 3.46% | 1.42M shares | |
| Insiders2 holders · as of Mar 12, 2026 | 16.65% | 6.84M shares | |
| Otherremainder | 79.89% | 32.81M shares |
41.06M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
14 holders · 1.42M shares · 4 new positions · 7 increased · 3 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 432.2K | 1.05% | +116.0K | May 15, 2026 |
| Vanguard Capital Management LLC | 408.1K | 0.99% | +408.1Knew | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 198.1K | 0.48% | +198.1Knew | May 8, 2026 |
| UBS Group AG | 107.8K | 0.26% | −113.1K | May 5, 2026 |
| Virtu Financial LLC | 84.2K | 0.21% | −5.7K | May 14, 2026 |
| XTX Topco Ltd | 47.7K | 0.12% | +47.7Knew | May 15, 2026 |
| Commonwealth Equity Services, LLC | 44.8K | 0.11% | 0 | Apr 27, 2026 |
| Two Sigma Securities, LLC | 36.4K | 0.09% | −14.4K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
